Physician profile
Steven H Eversley
NPI 1144205865
$10,348.52
in general payments reported to CMS, 2019-2025
48 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $858 · 2021: $1,929 · 2022: $1,430 · 2023: $1,503 · 2024: $1,726 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,007 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,007.31 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,262.83 | 2019-2025 | |
| Novo Nordisk INC | $1,145.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,001.59 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $914.19 | 2019-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $690.16 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $573.22 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $516.14 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.79 | 2019-2025 | Jardiance |
| Abbott Laboratories | $432.25 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $428.32 | 2019-2025 | |
| Amarin Pharma, INC. | $419.40 | 2019-2022 | |
| Amgen INC. | $297.54 | 2019-2025 | Evenity, Prolia, Prolia |
| Biohaven Pharmaceuticals, INC. | $214.61 | 2020-2021 | |
| Allergan, INC. | $189.42 | 2019-2020 | |
| Esperion Therapeutics, INC. | $172.15 | 2021-2025 | Nexletol |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Eversley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.